The gender-specific differences, MSI-dependent effects, and interactions with adjuvant chemotherapy underscore the complexity of MARCHF9's impact on survival outcomes in COAD patients, highlighting the need for personalized approaches in prognostic assessment and therapeutic decision making. This evidence concerns the gene MARCHF9 and colon adenocarcinoma.